Treatment of CRTH2-mediated diseases and conditions

A method for the treatment of a disease selected from the group consisting of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematus, acne, multiple sclerosis, allograft rejection, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis, comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (II):

• wherein
• R1, R2, R3 and R4 are independently hydrogen, halo, C1-C6 alkyl, —O(C1-C6 alkyl), —CON(R11)2, —SOR11, —SO2R11, —SO2N(R11)2, —N(R11)2, —NR11COR11, —CO2R11, —COR11, —SR11, —OH, —NO2 or —CN;
• each R11 is independently hydrogen or C1-C6 alkyl;
• R5 and R6 are each independently hydrogen, or C1-C6 alkyl or together with the carbon atom to which they are attached form a C3-C7 cycloalkyl group,
• R7 is hydrogen or C1-C6 alkyl;
• R8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C1-C6 alkyl, —O(C1-C6)alkyl, —CON(R11)2, —SOR11, —SO2R11, —SO2N(R11)2, —N(R11)2, NR11COR11, CO2R11, —COR11, —SR11, —OH, —NO2 or —CN;
• wherein R11 is as defined above;
• R9 is hydrogen, or C1-C6 alkyl;
• and
• R12 is C1-C6 alkyl, aryl, (CH2)mO(C═O)C1-C6alkyl, (CH2)mN(R13)2, CH((CH2)mO(C═O)R14)2;
• wherein
• m is 1 or 2;
• R13 is hydrogen or methyl;
• and
• R14 is C1-C18 alkyl;
• provided that:
• R8 is not phenyl substituted with —COOH;
• when any two of R1, R2, R3 and R4 are hydrogen, neither of the other two of R1, R2, R3 and R4 is C3-C6alkyl;
• or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.